Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 342 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar Sceaj (< 20) Submitted: 10/13/2014 10:15:07 AM : Outperform Start Price: $101.92 GILD Score: -0.56

Hep "C" drug - approved for Medicaid patients. That's huge.

Recs

0
Member Avatar PLocklar (22.79) Submitted: 10/12/2014 5:19:45 PM : Outperform Start Price: $104.49 GILD Score: -2.53

outperform

Recs

0
Member Avatar SegaRob (< 20) Submitted: 10/3/2014 1:03:42 PM : Outperform Start Price: $106.79 GILD Score: -1.52

Gilead's Hep C treatment is "top dog" and "first mover." Sofosbuvir (sovaldi) is a big hit and the new combo pill with Ledipasvir will be first all-oral and first interferon-free regimen for HCV. Moreover, it shows efficacy in all HCV genotypes. This is a huge potential! Also they have a successful portfolio of other drugs and track record making new drugs that will spur furtue growth. I am expecting EPS $8-10 in next year or so. Even with the big run this year, using a forward P/E ratio of 20, I think there's a good chance the stock could double in a few years or less from current prices under $107.

Recs

0
Member Avatar billney (< 20) Submitted: 10/2/2014 6:28:31 PM : Outperform Start Price: $103.42 GILD Score: +0.65

Rising Earning, Rising Value, Rising Price.

Recs

0
Member Avatar boomertom (20.39) Submitted: 9/30/2014 2:45:27 PM : Outperform Start Price: $106.22 GILD Score: -0.74

Superb company. Grossly undervalued.

Recs

0
Member Avatar qualityplustime (< 20) Submitted: 9/30/2014 2:12:57 AM : Outperform Start Price: $107.48 GILD Score: -1.60

GILD has begun to license Sovaldi (Hepititis C blockbuster) for sale in India and other large markets, I believe the earnings multiple will expand in Q4.

Recs

0
Member Avatar Googlespooch (< 20) Submitted: 9/29/2014 12:15:01 AM : Outperform Start Price: $107.59 GILD Score: -2.42

Strong HIV and Hep C portfolio. Impressive margins and growth prospects.

Recs

0
Member Avatar RugbyViking13 (85.76) Submitted: 9/27/2014 5:27:57 PM : Outperform Start Price: $107.59 GILD Score: -2.42

they make drugs that make money. Probably late to this party

Recs

0
Member Avatar Irish2014 (58.34) Submitted: 9/13/2014 9:23:38 AM : Outperform Start Price: $101.90 GILD Score: +4.24

Outperform due to Sovaldi utilization and other pipeline/expansion opportunities.

Recs

0
Member Avatar rbkearney (< 20) Submitted: 9/12/2014 2:01:17 PM : Outperform Start Price: $98.29 GILD Score: +2.39

Gilead's newest drug cures Hepatitis C. It's pricey--around $94,000 for full treatment--but still a better value than other options.

Recs

0
Member Avatar Morass (63.94) Submitted: 9/6/2014 9:14:03 PM : Outperform Start Price: $104.95 GILD Score: +2.19

GILD is a proven leader in biotech.

Recs

0
Member Avatar HILL6BILLY (< 20) Submitted: 9/5/2014 4:45:34 PM : Outperform Start Price: $104.95 GILD Score: +2.19

Earnings almost too good to be true......

Recs

0
Member Avatar calguy489 (< 20) Submitted: 9/2/2014 10:26:29 AM : Outperform Start Price: $108.47 GILD Score: -1.00

Great products

Recs

0
Member Avatar cipo (< 20) Submitted: 8/28/2014 9:56:02 AM : Outperform Start Price: $107.88 GILD Score: -0.95

the growth of free cash flow could lead to a successful dividend policy

Recs

0
Member Avatar irondistance (< 20) Submitted: 8/25/2014 3:30:51 PM : Outperform Start Price: $107.20 GILD Score: -0.19

SOVALDI

Recs

0
Member Avatar Stigshift (< 20) Submitted: 8/22/2014 3:26:17 PM : Outperform Start Price: $74.85 GILD Score: +33.84

real money pick

Recs

0
Member Avatar Toady (< 20) Submitted: 8/2/2014 11:44:47 PM : Outperform Start Price: $92.00 GILD Score: +11.79

Creating products that CURE people not just treat them (Hep C). Strong company with solid fundamentals. Very cheap stock with a ton of room to grow. Look at their pipeline, this company cares about growth and increasing value to their shareholders.

Recs

0
Member Avatar mrfore4471 (36.71) Submitted: 7/30/2014 12:01:52 PM : Outperform Start Price: $93.71 GILD Score: +11.47

When you create a drug that totally cures (in 98% of cases) a disease such as hepititas C, you know you've done something good. I hesitate extending the time frame because there seems to be some competitors who will probably accomplish this and for a cheaper price. In any case one of the research firms thinks this stock could hit $140.00 which obviously is pretty good.

Recs

1
Member Avatar shotgun06 (< 20) Submitted: 7/23/2014 4:20:17 PM : Outperform Start Price: $91.56 GILD Score: +15.25

Look at the products that they have and have in trials. The need for these products are very large!

Recs

1
Member Avatar shroff33 (< 20) Submitted: 7/20/2014 5:01:33 PM : Outperform Start Price: $89.80 GILD Score: +16.57

GILD will prevail over competition from ABBV and MRK.

Featured Broker Partners


Advertisement